MSD Sharp & Dohme GmbH Reports Findings in Human Papillomavirus Vaccines (Burden of CIN2+ diagnoses and conizations in women aged 18-45 years-a retrospective secondary data analysis of German statutory health insurance claims data): Immunization and Public Health – Human Papillomavirus Vaccines

2022 APR 22 (NewsRx) -- By a News Reporter-Staff News Editor at Information Technology Business Daily -- New research on Immunization and Public Health - Human Papillomavirus Vaccines is the subject of a report. According to news reporting from Munich, Germany, by NewsRx journalists, research stated, “High grade cervical intraepithelial neoplasia (CIN2+) may progress to cervical cancer. They may be detected by screening and are usually treated by conization.”

The news correspondents obtained a quote from the research from MSD Sharp & Dohme GmbH, “This study aimed at assessing annual proportions of screening, prevalent and incident CIN2+ diagnoses, as well as proportions of (re-)conizations during 24 months follow-up after conization in Germany. A descriptive retrospective claims data analysis of the years 2013-2018 was conducted using the InGef Research Database. Women aged 18-45 years with CIN2+ diagnoses were identified by ICD-10-GM codes (N87.1, N87.2, D06.-, and C53.-). Cervical conizations were identified by OPS codes (5-671.0* or 5-671.1*). Screening participation was identified by EBM codes (01730, 01733, 32819 or 32820). Annual proportions were calculated as women with the respective documented codes divided by all women in the respective age group per calendar year. Overall annual proportions of screened women spanned from 60.01 to 61.33% between 2013 and 2018. The overall annual prevalence of CIN2+ diagnoses (regardless of screening participation) ranged from 0.72 to 0.84% between 2013 and 2018, with highest proportions observed in women aged 27-45 years. Also, CIN2+ incidence was highest in women 27-45 years. Annual proportion of women undergoing conization was 0.24% in 2013 and 0.21% in 2018. During a 24-month follow-up period after conization, 2.91% of women underwent a re-conization 3 months or later after the initial conization. This analysis demonstrates a considerable burden of CIN2+, conizations and re-conizations in Germany, especially in women aged 27-45 years.”

According to the news reporters, the research concluded: “This highlights the need for intensified prevention efforts such as expanding human papillomavirus (HPV) vaccination.”

This research has been peer-reviewed.

For more information on this research see: Burden of CIN2+ diagnoses and conizations in women aged 18-45 years-a retrospective secondary data analysis of German statutory health insurance claims data. Archives of Gynecology and Obstetrics, 2022. Archives of Gynecology and Obstetrics can be contacted at: Springer Heidelberg, Tiergartenstrasse 17, D-69121 Heidelberg, Germany. (Springer - www.springer.com; Archives of Gynecology and Obstetrics - http://www.springerlink.com/content/0932-0067/)

Our news journalists report that additional information may be obtained by contacting Miriam Reuschenbach, Global Medical and Scientific Affairs, MSD Sharp & Dohme GmbH, Levelingstr. 4a, 81673, Munich, Germany. Additional authors for this research include Anna-Janina Stephan, Kunal Saxena, Vimalanand S. Prabhu, Christian Jacob, Kim Maren Schneider, Wolfgang Greiner, Regine Wolle and Monika Hampl.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1007/s00404-022-06548-7. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Publisher contact information for the journal Archives of Gynecology and Obstetrics is: Springer Heidelberg, Tiergartenstrasse 17, D-69121 Heidelberg, Germany.

(Our reports deliver fact-based news of research and discoveries from around the world.)